Description
Key facts
Cell type:A549,
Species or organism:Human,
Tissue:Lung,
Knockout validation:Sanger Sequencing,
Mutation description:Knockout achieved by using CRISPR/Cas9, 1 bp deletion in exon1 and 20 bp deletion in exon1.,
Disease:Carcinoma
Product details:
Knockout cell lysate achieved by CRISPR/Cas9.
REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
Lysate preparation:
Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10).
This means that the protein of interest is denatured.
If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.
User storage instructions:
Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.
This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our
limited use license
patent pages
Properties and Storage Information:
Gene name-HERC5, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Sanger Sequencing, Shipped at conditions-Ambient - Can Ship with Ice, Appropriate short-term storage conditions--20°C, Appropriate long-term storage conditions--20°C
Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
The HERC5 protein also known as HECT and RLD domain containing E3 ubiquitin protein ligase 5 functions mechanically as an E3 ubiquitin ligase involved in the post-translational modification process called ISGylation. It facilitates the attachment of ubiquitin-like protein ISG15 to target proteins. HERC5 has a molecular mass of approximately 112 kDa. Expression of HERC5 is mainly in human cells especially in high quantities in the spleen lung and kidney. The expression is often elevated by type I interferons indicating a role in immune response.
Biological function summary
The HERC5 protein contributes to innate immune response by modifying proteins involved in antiviral defense. It adds ISG15 to newly synthesized proteins marking them for rapid degradation or altering their activities. HERC5 operates as a solitary protein rather than forming part of a larger complex. Through its ISGylation activity HERC5 plays a significant role in enhancing the antiviral state of cells inhibiting viral replication and modulating cellular processes during stress responses.
Pathways
HERC5 actively integrates into the antiviral defense mechanism and ubiquitin-proteasome pathway. It associates with pathways related to protein modification and immune signaling significantly affecting how cells respond to viral infections. Proteins like ISG15 and ubiquitin-conjugating enzymes interact with HERC5 in these pathways highlighting its importance in maintaining cellular homeostasis and protecting against pathogens.
The HERC5 protein shows connections with viral infections and certain inflammatory conditions. Its heightened activity associates with viral diseases like influenza and hepatitis where enhanced ISGylation occurs as a defensive strategy against viral proliferation. Misregulation of ISGylation through HERC5 also relates to neuroinflammatory disorders suggesting that targeting this pathway may offer therapeutic potential. Researchers continue exploring the interaction of HERC5 with proteins linked to these conditions to better understand its impact on disease progression and potential interventions.
